CytomX Therapeutics Overview
CytomX Therapeutics Target Price
CytomX Therapeutics target price — quarterly history, peer benchmarks, and growth trends.
Get informed when a big investor buys or sells
+ FollowShare Price
$2.94
Average Target Price
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2026-05-19 | Wolfe Research | $6 |  104.1% upside |  |
| 2026-05-11 | H.C. Wainwright | $11 | 274.1% upside | |
| 2026-03-18 | JefferiesRoger Song | $16 | 444.2% upside | |
| 2026-03-16 | OppenheimerMatthew Biegler | $12 | 308.2% upside | |
| 2026-02-04 | Barclays | $10 | 240.1% upside | |
| 2026-01-20 | Piper Sandler | $10 | 240.1% upside | |
| 2026-01-20 | GuggenheimMichael Schmidt | $10 | 240.1% upside | |
| 2026-01-20 | BarclaysEtzer Darout | $8 | 172.1% upside | |
| 2025-10-21 | BarclaysEtzer Darout | $6 | 104.1% upside | |
| 2025-09-16 | BarclaysEtzer Darout | $3.5 | 19% upside | |
| 2025-07-31 | OppenheimerMatthew Biegler | $7 | 138.1% upside | |
| 2024-11-08 | BMO CapitalEtzer Darout | $3.68 | 25.2% upside | |
| 2024-11-08 | Piper SandlerJoseph Catanzaro | $3.25 | 10.5% upside | |
| 2024-08-09 | BMO CapitalEtzer Darout | $3.56 | 21.1% upside | |
| 2024-05-27 | Piper SandlerJoseph Catanzaro | $3.5 | 19% upside | |
| 2024-05-09 | BMO CapitalEtzer Darout | $3.59 | 22.1% upside | |
| 2024-05-09 | WedbushRobert Driscoll | $8 | 172.1% upside | |
| 2024-05-05 | JefferiesRoger Song | $8 | 172.1% upside | |
| 2024-03-12 | JefferiesRoger Song | $2.5 |  15% downside | |
| 2024-03-12 | BMO CapitalEtzer Darout | $3.25 | 10.5% upside | |
| 2023-01-06 | BMO Capital | $3.2 | 8.8% upside | |
| 2022-11-14 | BMO Capital | $2.6 | 11.6% downside | |